These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1348994)

  • 1. Clinical application of a gonadotropin releasing hormone analog (buserelin) in the treatment of uterine leiomyomas.
    Acar B; Posaci C
    Int J Gynaecol Obstet; 1992 May; 38(1):52-3. PubMed ID: 1348994
    [No Abstract]   [Full Text] [Related]  

  • 2. [Shrinkage of uterine leiomyomas after intranasal administration of a LHRH agonist].
    Uemura T; Kimura A; Shirasu K; Minaguchi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):365-8. PubMed ID: 2499643
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
    Nakamura Y; Yoshimura Y
    Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
    [No Abstract]   [Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
    Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
    Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
    Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.
    Maheux R; Lemay A; Merat P
    Fertil Steril; 1987 Feb; 47(2):229-33. PubMed ID: 3102282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
    Friedman AJ; Lobel SM; Rein MS; Barbieri RL
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
    Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GnRH-analogs in the therapy of uterine myomatosis].
    Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
    Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R; Lemay A
    Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
    Maheux R; Lemay A; Turcot-Lemay L
    Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH; Shaw RW; Nye M
    Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
    Puzigaća Z; Prelević GM; Sretenović Z
    Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
    Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
    Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
    Rolland R; Franssen AM; Willemsen WN; Corbey RS
    Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
    [No Abstract]   [Full Text] [Related]  

  • 18. Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin-releasing hormone.
    Sakamoto S; Mitamura T; Iwasawa M; Kitsunai H; Shindou K; Yagishita Y; Zhou YF; Sassa S
    In Vivo; 1998; 12(3):333-7. PubMed ID: 9706480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
    Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
    Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
    Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
    Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.